Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about DICE Therapeutics, Inc.
DICE Therapeutics, Inc. News
Aug 9, 2023 - prnewswire.com
Lilly Completes Acquisition of DICE Therapeutics
Jul 25, 2023 - prnewswire.com
Lilly Announces Extension of Tender Offer to Acquire DICE
Jul 12, 2023 - marketwatch.com
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
Jul 10, 2023 - businesswire.com
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
DICE Therapeutics, Inc. Quantitative Score
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
DICE Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
DICE Therapeutics, Inc. Financials
Table Compare
Compare DICE metrics with: | |||
|---|---|---|---|
Earnings & Growth | DICE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | DICE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | DICE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | DICE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
DICE Therapeutics, Inc. Income
DICE Therapeutics, Inc. Balance Sheet
DICE Therapeutics, Inc. Cash Flow
DICE Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
DICE Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. J. Kevin Judice Ph.D. | Founder, Chief Executive Officer & Director |
| Dr. Timothy Lu M.D., Ph.D. | Chief Medical Officer |
| Mr. Scott Robertson | Chief Bus. & Financial Officer |
| Dr. John R. Jacobsen Ph.D. | Chief Scientific Officer |
| Ms. Mary Riley J.D. | Gen. Counsel |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. J. Kevin Judice Ph.D. | Founder, Chief Executive Officer & Director | 1964 | 840K | |
| Dr. Timothy Lu M.D., Ph.D. | Chief Medical Officer | 1975 | 700K | |
| Mr. Scott Robertson | Chief Bus. & Financial Officer | Male | 690K | |
| Dr. John R. Jacobsen Ph.D. | Chief Scientific Officer | 1969 | -- | |
| Ms. Mary Riley J.D. | Gen. Counsel | Female | -- |
DICE Therapeutics, Inc. Insider Trades
| Date | 9 Aug |
| Name | RA CAPITAL MANAGEMENT, L.P. |
| Role | |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 786407 |
| Date | 9 Aug |
| Name | RA CAPITAL MANAGEMENT, L.P. |
| Role | |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 21250 |
| Date | 9 Aug |
| Name | TETLOW SHARON |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 49841 |
| Date | 9 Aug |
| Name | TETLOW SHARON |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 13800 |
| Date | 9 Aug |
| Name | TETLOW SHARON |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 21250 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Aug | RA CAPITAL MANAGEMENT, L.P. | Disposed | U-Tender | 786407 | |
| 9 Aug | RA CAPITAL MANAGEMENT, L.P. | Disposed | D-Return | 21250 | |
| 9 Aug | TETLOW SHARON | Director | Disposed | D-Return | 49841 |
| 9 Aug | TETLOW SHARON | Director | Disposed | D-Return | 13800 |
| 9 Aug | TETLOW SHARON | Director | Disposed | D-Return | 21250 |